The biosimilar market in 2026: what has changed for companies entering from small molecules

For most of the last decade, entering the biosimilar market meant licensing someone else's product. That pattern changed through the first half of 2026. Regulatory requirements eased, more approvals arrived, and several companies concluded that owning development and manufacturing capability was worth more than paying for access to it.

Capability is being bought rather than licensed

The two largest transactions in the first half of 2026 were both in April: an agreement to acquire Kashiv BioSciences for approximately USD 1.1 billion in total potential consideration, and an agreement to acquire Organon in an all-cash transaction at an enterprise value of USD 11.75 billion. Both remain proposals subject to shareholder and regulatory approval, but the direction is clear. The strategic logic is straightforward: control of development capability, manufacturing capacity and commercial reach is what separates a company able to launch a broad portfolio from one that depends on terms set by other parties. For a company that has spent years licensing, the alternative to buying is remaining a licensee — and the licensing counterparties are now themselves buying, which changes what is available to license.

Approval no longer differentiates

With 89 biosimilars approved as of October 2026 and multiple competitors on several molecules, an approval is a ticket to compete rather than an advantage. Eight adalimumab biosimilars have already captured a substantial share of the reference product's United States volume, and in a class where eight products already compete, differentiation has largely moved to formulary access, contracting, supply reliability and litigation outcomes. It is worth being clear-eyed about this: in a mature biosimilar class the commercial question is no longer who can obtain approval but who can obtain formulary position, and the pricing strategy that follows from it.

Newly opened classes are a different proposition

The first United States biosimilars in several classes were approved in the first half of 2026, including golimumab, an interchangeable insulin glargine, an interchangeable ranibizumab and additional denosumab, filgrastim and pegfilgrastim entrants. In a newly opened class, the question of how fast price erosion and share shift occur is still open, and the answer will be instructive. There is also a specific, measurable opportunity in a class where several products already compete: the eighth United States pegfilgrastim biosimilar will show what differentiation remains available in a category where price is already compressed. For a company considering entry, the timing question is when — a newly opened class with a first wave of competitors is a different commercial proposition from a mature one.

What a company without biologics experience should actually assess

Three things. Whether the analytical and comparability package can be built in-house or requires a partner, because the regulatory direction of travel favours sponsors with genuine characterisation and pharmacokinetic capability rather than licensed data alone. Whether manufacturing capacity is available, because the constraint in this market has shifted from development to supply, and a sponsor that cannot supply reliably does not convert a formulary position into volume. And whether the commercial footprint already exists, because in a market where the differentiator is formulary access, a company without access infrastructure carries a cost that does not appear in the development budget. None of these questions has a single right answer, but each should be asked explicitly before committing, because the failures in this sector have generally come from answering them implicitly.

This article reflects published market research and public company announcements and does not constitute legal, regulatory or investment advice. Transactions described as announced remain subject to shareholder and regulatory approval, and market conditions in this sector change quickly. Confirm current requirements and current market status before acting.